about
Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetesPrediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.Twenty-Year Progression Rate to Clinical Onset According to Autoantibody Profile, Age, and HLA-DQ Genotype in a Registry-Based Group of Children and Adults With a First-Degree Relative With Type 1 Diabetes.Hyperglycemic clamp and oral glucose tolerance test for 3-year prediction of clinical onset in persistently autoantibody-positive offspring and siblings of type 1 diabetic patients.Correction: Prediction of Impending Type 1 Diabetes through Automated Dual-Label Measurement of Proinsulin:C-Peptide Ratio.Relationship between glycaemic variability and hyperglycaemic clamp-derived functional variables in (impending) type 1 diabetes.Glucose Complexity Estimates Insulin Resistance in Either Nondiabetic Individuals or in Type 1 Diabetes.Susceptibility of Burkholderia cepacia Complex Isolated from Cystic Fibrosis Patients to Ceftazidime-Avibactam and Ceftolozane-TazobactamPerformance evaluation of the prototype Abbott Alinity hq hematology analyzer
P50
Q35207904-388DABC8-0ACA-42C2-AB1E-B9AE0CE14B9CQ36209699-E421936D-0771-4630-9622-14C69C7529DCQ38682088-E6D52429-F030-4EF0-AD9D-1DCD9857F50AQ39096821-EFDF3490-7193-402F-A63C-E28099441238Q42343992-00F7AD18-CE43-46FE-962C-BC08C6E7E9F3Q49110588-382AB624-496A-4A55-AF2F-A3E4A9CD39ADQ53798176-C68B0E52-8BE7-4D47-B02B-F5D4929A3052Q60332428-445896FC-ED5D-4446-99CE-582ACC6349D1Q91874557-32A24352-C2A7-4D33-880B-786A777AC08C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Annelien Van Dalem
@en
Annelien Van Dalem
@nl
type
label
Annelien Van Dalem
@en
Annelien Van Dalem
@nl
prefLabel
Annelien Van Dalem
@en
Annelien Van Dalem
@nl
P31
P496
0000-0003-2304-5298